Medications That Can Cause Hair Loss
Hair loss is a recognized side effect of dozens of common medications. Some have it explicitly on their labels; others have well-documented observations in the medical literature; others are uncertain. The mechanism is almost always telogen effluvium, a diffuse synchronized shedding triggered two to three months after starting the medication, which then resolves if the drug is stopped or sometimes continues unchanged on the same medication. A separate, more dramatic mechanism (anagen effluvium) is the basis for chemotherapy-related hair loss.
This page covers the main medication categories associated with hair loss, the timing and pattern that distinguishes drug-induced shedding from other causes, and the practical framework for figuring out whether a medication you take is contributing. The drug-induced hair loss cluster has dedicated child pages for the highest-volume specific drugs.
How drug-induced hair loss usually presents
The telogen effluvium pattern that medications most commonly cause has a recognizable signature:
- Onset two to three months after starting the medication. The delay reflects the length of the telogen phase: the drug pushes follicles into telogen, and they shed about three months later.
- Diffuse shedding across the whole scalp, not the focal temple-and-crown pattern of androgenetic alopecia.
- No symptoms. The scalp itself does not itch, hurt, or change appearance beyond density loss.
- Coincides with no other obvious trigger (illness, surgery, weight loss, major stressor), or coincides with the medication change but not those.
Drug-induced shedding is usually reversible. Stopping the medication, when clinically appropriate, generally resolves the shedding within three to six months, although the recovered density may take longer to be fully visible.
The framework for distinguishing drug-induced hair loss from other causes is timing (months after starting the drug), pattern (diffuse, not patterned), and the absence of other triggers.
Common medication categories
The categories below are not exhaustive but cover the most common offenders. The strength of the evidence varies; some categories have clear pharmacovigilance signals, while others have weaker observations.
GLP-1 weight loss medications (semaglutide, tirzepatide). Hair loss is increasingly reported with these drugs, and the labeling for both medications now includes alopecia as a possible adverse effect. The underlying mechanism appears to be more about rapid weight loss than the drug itself: any rapid weight loss is a recognized telogen effluvium trigger. The companion GLP-1 and hair loss guide covers this in detail.
Metformin. Hair loss with metformin is mediated through vitamin B12 deficiency: metformin can reduce B12 absorption over time, and B12 deficiency can drive hair shedding. The fix is usually B12 supplementation rather than stopping metformin, since the underlying diabetes management matters more than the hair effect.
Antidepressants. SSRIs, SNRIs, bupropion, and tricyclic antidepressants have all been associated with telogen effluvium in some users. The signal is stronger for some specific drugs (bupropion has a more prominent association than escitalopram, for example) but is variable across patients.
Birth control. Hair changes can occur in either direction. Pills with high-androgenicity progestins (older norethindrone-based pills) can drive pattern hair loss in susceptible women. The transition on or off any hormonal contraceptive can trigger telogen effluvium.
Blood thinners. Warfarin and heparin both have hair loss reported as side effects, with warfarin having a more consistent signal. Direct oral anticoagulants (DOACs) like apixaban and rivaroxaban have less data but occasional reports.
Beta blockers (propranolol, metoprolol) and ACE inhibitors (lisinopril) have hair loss listed in their labeling and occasional published reports, though the absolute incidence is low.
Statins. The signal is weaker than for the above categories but real. Atorvastatin and simvastatin have occasional reports of telogen effluvium.
Anticonvulsants. Valproate (used for seizures and bipolar disorder) and gabapentin (used for nerve pain, anxiety, and seizures) both have hair-loss signals, with valproate's being stronger.
Retinoids. Oral isotretinoin (used for severe acne) and high-dose vitamin A supplements can cause telogen effluvium that may persist while the medication is being taken.
Chemotherapy. This is a distinct mechanism, anagen effluvium, in which actively growing hair shafts are damaged directly. The shedding is rapid and often dramatic, beginning within weeks of starting treatment. It usually recovers fully after chemotherapy ends, sometimes with temporary changes in hair color or texture.
Hormonal therapies for cancer (tamoxifen, aromatase inhibitors). Used for breast cancer treatment and prevention. Hair shedding is a recognized side effect, often persisting as long as the medication is taken (typically 5 to 10 years).
Working out whether a medication is the cause
A practical framework when you suspect medication-induced hair loss:
The first question is timing. Did the shedding start two to three months after a new medication, a dose change, or a change in regimen? Drug-induced telogen effluvium has a characteristic delay; shedding that started before the medication began is not drug-induced.
The second question is pattern. Is the shedding diffuse across the whole scalp, or is it concentrated at the temples and crown? Drug-induced hair loss is almost always diffuse. A patterned distribution suggests androgenetic alopecia (which can be unmasked by the drug-induced shedding but is the underlying process).
The third question is what else changed. New medications, recent illness, rapid weight loss, recent surgery, a major life stressor, or pregnancy and delivery can all trigger telogen effluvium independently. If multiple potential triggers coincided, the analysis is less clean.
The fourth question is whether the medication is essential. If yes (a beta blocker for heart failure, a chemotherapy regimen, hormonal therapy for cancer), the conversation with the prescribing physician is about how to manage the hair effect rather than whether to stop the drug. If no (a discretionary medication for a non-life-threatening condition), the prescribing physician can discuss whether trial discontinuation is reasonable.
The fifth question is what the labs show. A focused panel (CBC, ferritin, TSH, vitamin D, vitamin B12) rules in or out the most common alternative causes and identifies deficiencies (particularly B12 in metformin users) that can be treated independently.
Do not stop medications without a conversation
The single most important practical caveat: do not stop a medication on your own to test whether it is causing hair loss. Many of the medications on the list above are taken for important reasons (blood pressure control, anticoagulation, cancer treatment, mood stabilization), and abrupt discontinuation can have serious consequences. Trial discontinuation is sometimes the right move, but it is a decision made with the prescribing physician, often with a substitute drug ready to start if needed.
When the picture is mixed
A relatively common scenario is a person taking several medications who develops gradual or fluctuating shedding over months to years. The contribution of any one drug can be hard to disentangle. The pragmatic approach is to identify and address modifiable contributors (low B12 on metformin, treatable iron or thyroid abnormalities), evaluate for coexisting pattern hair loss, and then decide whether any medication changes are worth attempting.
The companion overview of drug-induced hair loss covers each medication category in more depth, and a structured medical assessment is usually the most efficient way to sort the differential. Curekey's hair assessment is one way to start with a U.S.-licensed physician.
When to consult
If shedding has clearly started within months of a new medication and the pattern is diffuse, that is a reasonable trigger for a conversation with the prescribing physician. If the medication is non-essential, a trial discontinuation can clarify whether it is contributing. If the medication is essential, the conversation shifts to managing the hair effect with treatment of any coexisting pattern hair loss and addressing modifiable contributors. Most drug-induced hair loss is reversible; the priority is identifying it accurately so the right next step is clear.
